ATLANTA, GA – – (ACCESSWIRE – May 5, 2022) – – Holzer & Holzer, LLC is investigating whether HUTCHMED Limited (“HUTCHMED” or the “Company”) (NASDAQ: HCM) complied with federal securities laws.  On May 2, 2022, HUTCHMED announced that the FDA issued a Complete Response Letter regarding its New Drug Application. According to HUTCHMED, the FDA determined that the Company’s current data package does not support approval in the U.S. and that a multi-regional clinical trial that includes subjects more representative of the U.S. patient population is required.  Following this announcement, the Company’s stock price dropped. If you purchased HUTCHMED stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  or Joshua Karr, Esq. at, call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.

Provide Your Information To Take Action

  • Date PurchasedNumber of Shares AcquiredAcquisition Price Per Share 
  • Date SoldNumber of Shares SoldSelling Price Per Share 
  • Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt